• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

GSK-3 β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma.
In conclusion and to the best of our knowledge, the current study was the first to determine that GSK-3β is a target gene of HNF-1β. In addition, the results of the present study revealed the novel HNF-1β-GSK-3β-p-NFκB pathway, occurring in response to DNA damage. Targeting this pathway may therefore represent a putative, novel, anticancer strategy in patients with OCCC. PMID: 33005248 [PubMed]
Source: Experimental and Therapeutic Medicine - October 4, 2020 Category: General Medicine Tags: Exp Ther Med Source Type: research

ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin.
Authors: Lyu C, Zhang Y, Zhou X, Lang J Abstract In ovarian clear cell carcinoma (OCCC), the mutation rate of the AT-rich interaction domain 1A (ARID1A) gene is 46-57%. However, the effects of ARID1A gene silencing by small interfering RNA (siRNA) on the sensitivity of OCCC to cisplatin have not been investigated. Thus, this study aimed to elucidate the association between ARID1A gene silencing and drug resistance in OCCC. Three pairs of ARID1A gene siRNA fragments (siRNA-1, siRNA-2 and siRNA-3) were designed and transiently transfected into ES2 OCCC cells using RNAi Max reagent. Western blotting results demonstrat...
Source: Experimental and Therapeutic Medicine - January 22, 2017 Category: Journals (General) Tags: Exp Ther Med Source Type: research